Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
1. Moderna's stock dropped 19.20% after pipeline updates. 2. The company expects lower R&D spending, affecting future growth. 3. Projected revenues for 2025 are $1.5 billion to $2.5 billion, below estimates. 4. Moderna aims for ten product approvals by 2025 in prioritized sectors. 5. Overall performance showed stable Q3 revenues compared to last year.